Ergoteles LLC Has $1.03 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Posted by Defense World Staff on Feb 27th, 2023

Ergoteles LLC lessened its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 77.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,288 shares of the biotechnology company’s stock after selling 31,661 shares during the period. Ergoteles LLC’s holdings in Sarepta Therapeutics were worth $1,027,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of SRPT. Hanseatic Management Services Inc. bought a new position in Sarepta Therapeutics during the third quarter worth about $35,000. Cullen Frost Bankers Inc. acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter worth approximately $44,000. C M Bidwell & Associates Ltd. increased its holdings in shares of Sarepta Therapeutics by 1,966.7% during the 2nd quarter. C M Bidwell & Associates Ltd. now owns 620 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 590 shares during the last quarter. Altshuler Shaham Ltd bought a new stake in Sarepta Therapeutics in the 3rd quarter valued at $58,000. Finally, Nkcfo LLC acquired a new stake in Sarepta Therapeutics during the 3rd quarter valued at $85,000. 87.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SRPT has been the topic of several research analyst reports. BTIG Research increased their price objective on shares of Sarepta Therapeutics from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, December 22nd. Cantor Fitzgerald raised their price objective on shares of Sarepta Therapeutics from $150.00 to $174.00 in a research report on Tuesday, December 13th. SVB Leerink restated an “outperform” rating and set a $160.00 price objective on shares of Sarepta Therapeutics in a report on Friday, January 20th. Robert W. Baird increased their target price on Sarepta Therapeutics from $110.00 to $152.00 in a research note on Thursday, November 3rd. Finally, Cowen boosted their price target on Sarepta Therapeutics from $114.00 to $125.00 in a research note on Wednesday, January 11th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $151.79.

Sarepta Therapeutics Stock Down 1.4 %

Shares of NASDAQ SRPT opened at $123.06 on Monday. The stock has a market capitalization of $10.80 billion, a P/E ratio of -14.99 and a beta of 0.98. The stock’s fifty day moving average is $124.49 and its 200 day moving average is $116.73. Sarepta Therapeutics, Inc. has a 52 week low of $61.28 and a 52 week high of $134.08. The company has a debt-to-equity ratio of 3.58, a quick ratio of 3.99 and a current ratio of 4.36.

Sarepta Therapeutics Company Profile

(Get Rating)

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.